Symptoms appear in patients their mid-60s. Scientists believe that for most people, Alzheimer’s disease is caused by a combination of genetics, lifestyle and environmental factors.
Nearly 6 million Americans suffer from the disease. World-wide 44 million people have Alzheimer’s and dementia-related conditions. It is the sixth leading cause of death in the United States. There is no cure.
Cx Precision Medicine has developed an effective blood-based Alzheimer’s test which gives patients and their primary care doctors a tool to “rule-out” the existence of the disease in a patient for a more accurate diagnosis of the patient’s condition.
Symptoms include shaking, stiffness, difficulty with walking, balance and coordination which worsen over time. As the disease progresses, people also may have mental and behavioral changes, depression, and memory difficulties. Many people with Parkinson’s first develop the disease at about 60. Some cases appear to be hereditary, and a few can be genetic, and in most cases the disease occurs randomly. There is no cure.
More than one million Americans are living with the disease and about 60,000 people are diagnosed in the US annually. An estimated 7-10 million people world-wide have Parkinson’s disease.
Cx Precision Medicine is developing a “rule-out” blood diagnosis test for Parkinson’s based on the technology used in its successful Alzheimer’s test.
This blood test will determine that a person with memory concerns does not have Alzheimer’s Disease, granting them and their families peace of mind, and sparing them costly and invasive forms of testing.
This blood test will determine that a person with neuromuscular or memory concerns does not have Parkinson’s Disease, granting them and their families peace of mind, and sparing them costly and invasive forms of testing.
This blood test will enable physicians to determine the most appropriate drug-based therapies for Alzheimer’s patients based on the patient’s unique genetic and biochemical presentation of the disease – a true Precision Medicine approach to effective disease management.
Scheduled launch late 2021/early 2022